Raduenz Brian

Director Raduenz Brian bought 50,000 shares of AVEX at $20.00 ($1.0M); 4 other insiders also bought within 14 days.

Raduenz Brian, a director of AEVEX Corp., purchased 50,000 shares at $20.00 totaling $1,000,000 on 2026-04-16, establishing an initial position. This buy occurs in the context of a broader pattern: 4 other insiders also bought within the past 14 days, forming a cluster buy signal. The stock is in very early trading (2 days post-listing at $33.41 current price), making this an early-stage post-IPO insider accumulation event. Concurrent buying by multiple insiders in the immediate post-listing window represents concentrated insider capital allocation in a company's formative public market period.

KRMN Director Raduenz sold 90,000 shares at $68.00 on 2025-11-12 for $6.1M; stock down 31.1% from 52-week high, -22.1% in 30 days.

Director Brian Raduenz sold 90,000 shares (26.2% of his pre-transaction holdings) at $68.00, reducing his stake from 344,105 to 254,105 shares. This is his second open-market transaction at KRMN; his prior sale on 2025-07-25 was poorly timed (the stock returned +67.3% over the next 90 days, meaning he sold before a rally). The current transaction follows sharp recent price declines: KRMN is down 31.1% from the 52-week high of $87.04 and down 22.1% over the past 30 days, suggesting the stock has deteriorated significantly since his prior sale. The company's fundamentals show revenue growth of +23.0% year-over-year and a $7.9B market cap, but with a P/E ratio of 666.56 (highly elevated), raising questions about valuation. The timing of this sale against the stock's recent downtrend and his outsized P/E multiple differs materially from the conditions present at his July 2025 sale.

Director Raduenz Brian sold 34,032 shares of KRMN at $49.00 on 2025-07-25, reducing stake to 378,137 shares post-transaction.

Raduenz Brian, a Director, sold 34,032 shares at $49.00, representing 8.3% of his prior holdings and generating $1,667,568.00 in proceeds. The transaction occurred $2.41 below the current price of $51.41, at a level within the 52-week trading range and 8.7% below the 52-week high of $56.30. The stock has risen 1.9% over the past 30 days and 43.8% over the past 90 days, placing this sale within a broader uptrend. Investors should note the company's recent net loss of $4,798,000.00 on $100,124,000.00 quarterly revenue alongside strong 23.0% annual revenue growth, which indicates margin pressure despite topline expansion, and the elevated P/E of 1285.25 reflects near-breakeven profitability.